Research programme: proteome-based therapeutics - Roche/Vividion Therapeutics
Latest Information Update: 28 Jun 2024
At a glance
- Originator Vividion Therapeutics
- Developer Roche; Vividion Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
- No development reported Immunological disorders
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in Immunological-disorders in USA